MSB 4.69% $1.45 mesoblast limited

Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain, page-194

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 35,472 Posts.
    lightbulb Created with Sketch. 2863
    I decided to check on your "claim" with facts which I called BS, as you do tend to exaggerate in your posts....

    "We are treating patients in the Phase 3 trial with back pain so advanced their only real alternative choice is interventional surgery like spinal fusion"

    Yet here is the main inclusion criteria from actual trial....

    "Have documented diagnosis of moderate radiographic degeneration of an intervertebral disc from L1 to S1, with a disc suspected of causing CLBP Chronic low back pain associated with moderate radiographic degeneration at a lumbar disc"

    https://clinicaltrials.gov/ct2/show/NCT02412735

    Good you have added your disclaimer to end your posts recently.biggrin.png

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.